Quanterix announces termination of license agreement with bioMérieux

Secures and consolidates unrestricted rights for Simoa technology in diagnostics market. Quanterix a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced the consolidation of its licensing position and reestablishment of control of its intellectual property in the in vitro diagnostics (IVD) field. The termination of the license agreement by bioMérieux reinstates to Quanterix all rights and privileges associated with its Simoa technology.

While we have benefited from our six-year strategic relationship with bioMérieux for commercializing Simoa into IVD markets, this development unlocks our long-term value creation opportunity in the estimated $30B IVD market,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “Over the last several years we have built a formidable business and momentum in research use only (RUO) markets validating our technology’s disruptive potential in neurology, oncology, infectious disease, inflammation and immune disorders, while bioMérieux’s investments have been integral in advancing the Simoa technology in IVD. Quanterix now has strategic optionality to capitalize on a broad range of IVD markets and opportunities beyond bioMérieux’s primary focus of infectious disease and immunology. We look forward to continuing our close collaboration with bioMérieux as it remains one of our strongest customers for Simoa.